Concepedia

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

Ian J. Neeland, Darren K. McGuire, Robert Ćhilton, Susanne Crowe, Søren S. Lund, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen

Diabetes and Vascular Disease Research · 2015 · 160 citations · 19 references

DOIFull text

Open access

Abstract

Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.

References

19

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 11.6K citations · Full text

Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes

Philip R. Schauer, Sangeeta R. Kashyap, Kathy Wolski et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Visceral Adiposity Index

Marco Calogero Amato, Carla Giordano, Massimo Galia et al. · Diabetes Care · 2010 · 1.7K citations · Full text

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon et al. · The Lancet · 2013 · 718 citations

, , +8

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Jan Bolinder, Östen Ljunggren, Lars Johansson et al. · Diabetes Obesity and Metabolism · 2013 · 470 citations · Full text